Results 1 to 10 of about 85,679 (96)
Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity [PDF]
LifeGenetic variation may contribute to interindividual differences in the efficacy and tolerability of glucagon-like peptide-1 receptor agonists (GLP-1RAs), although the available evidence remains limited.
Mónica T. Fernandes +4 more
doaj +2 more sources
GLP‐1 Medicines in Perspective: Approaches to Optimize Outcome [PDF]
Journal of DiabetesZachary Bloomgarden
doaj +2 more sources
Age and Gender Effects on Genotoxicity in Diesel Exhaust Particles Exposed C57BL/6 Mice
Biomolecules, 2021 There is growing evidence that the accumulation of DNA damage induced by fine particulate matter (PM2.5) exposure is an underlying mechanism of pulmonary disease onset and progression.
Joong Won Lee +8 more
doaj +1 more source
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. [PDF]
PLoS ONE, 2010 GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2168 h. Intraperitoneal glucose tolerance test (IPGTT) in mice showed that GLP-1/hIgG2 significantly decreased ...
Qinghua Wang +6 more
doaj +1 more source
Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. [PDF]
PLoS ONE, 2013 Glucagon-like-peptide-1 (GLP-1) is a gut- and neuro-peptide with an important role in the regulation of food intake and glucose metabolism. Interestingly, GLP-1 receptors (GLP-1R) are expressed in key mesolimbic reward areas (including the ventral ...
Rozita H Shirazi +2 more
doaj +1 more source
Microbial Biotechnology, 2023 Hypertension is a significant risk factor of cardiovascular diseases (CVDs) with high prevalence worldwide, the current treatment has multiple adverse effects and requires continuous administration.
Xin‐liang Wang +8 more
doaj +1 more source
Pharmaceuticals, 2022 Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun +8 more
doaj +1 more source
Frontiers in Physiology, 2020 Glucagon-like peptide 1 (GLP-1) in addition to regulating glucose-dependent insulin and glucagon secretion exerts anorexic and neuroprotective effects.
Zhuo Fu +8 more
doaj +1 more source
Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor. [PDF]
PLoS ONE, 2012 Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R).
Naichang Li, Jing Lu, Gary B Willars
doaj +1 more source